Join us for an exciting and informative Summer Pathology Conference taking place on July 17-18, 2021 at the Eau Palm Beach Resort & Spa in Palm Beach. Hear interesting cases and learn new diagnostic strategies in breast pathology, genitourinary pathology and obstetric and gynecologic pathology to make an impact in your practice or organization.
NEW IN 2021 attendees will be able to take part in an interactive roundtable discussion led by senior pathologists on medical malpractice. Attendees will hear how to respond to diagnostic errors and how to deal with the impact and stress of a malpractice situation.
In addition to the educational offerings, attendees will have an opportunity to connect with colleagues and interact with industry leaders in the field of pathology during exhibit hall social functions.
|Abstract Poster Submission #1|
|Disclosure of Funding Support|
|Choose one of the following Topics|
Timothy Craig Allen, MD, JD
Professor and Chair
University of Mississippi Medical Center
Rebekah Bernard, MD
Gulf Coast Direct Primary Care
Fort Myers, Florida
Christopher P. Crum, MD
Professor of Pathology, Harvard Medical School
Division of Women's and Perinatal Pathology
Department of Pathology
Brigham and Women's Hospital
Topic: GYN Pathology
Julia V. Hegert, M.D.
Director of Autopsy Pathology, Orlando Health
Topic: COVID-19 Autopsies: Aide to the Living through Proper Examination of the Dead
Merce Jorda, MD, PhD, MBA
Professor and Chair
Department of Pathology & Laboratory Medicine
Director of Genitourinary Pathology and Cytopathology
Chief of Pathology, Jackson Memorial Hospital
University of Miami Miller School of Medicine
Topic: GU Pathology
Aysegul A. Sahin, MD
Section Chief of Breast Pathology
Division of Pathology/Lab Medicine
The University of Texas MD Anderson Cancer Center
Topic: Breast pathology
Luis Villa Jr., MD
Pathologist and Clinical Oncologist
University of Miami Miller School of Medicine
Coral Gables, FL
Jim Zhai, MD, FCAP
Professor of Lab Medicine and Pathology
Mayo Clinic Florida
Florida Society of Pathologists
Saturday, July 17, 2021
7:00 a.m. - 7:45 a.m.
Understanding Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Evolving Molecular Insights and Diagnosis of an Aggressive Hematologic Malignancy
Alejandro Gru, MD
Sponsored by: Stemline Therapeutics
An intimate ocean retreat, situated on the sweeping back drop of Florida’s gold coast and with the Atlantic as its playground, Eau Palm Beach invokes the relaxed glamour of America’s first resort destination; a chance to refresh, play and rediscover time. One of only two Forbes Five-Star resorts in Palm Beach and eight in Florida, Eau Palm Beach Resort & Spa is where effortless living meets relaxed luxury. Situated on a private beach on seven acres of oceanfront with lush tropical gardens, guests are welcomed with champagne, breathtaking ocean views and cooling tropical breezes. Indulge in the warm Florida sunshine, sumptuous accommodations designed by Jonathan Adler, and the award-winning Eau Spa.
Eau Palm Beach Resort & Spa
100 S Ocean Blvd, Manalapan, FL 33462
FSP Discounted Room Rate: $219/night (plus tax)
Click here or call 855-388-0537 to reserve your hotel room at the FSP discounted room rate. The special rate is available until June 15, 2021 or until the block is filled.
The health and safety of our hoteliers, guests and community remains Eau Palm Beach Resort & Spa’s highest priority. By closely monitoring the latest guidelines by the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and the State of Florida and Palm Beach County Departments of Health, we’ve implemented the Safe Stay Program at Eau Palm Beach Resort & Spa. This rigorous new protocol is intended to keep you safe and healthy during your visit so that you can focus on creating lasting memories at our Forbes Five-Star, AAA Five Diamond ocean retreat.
For more details on the Safe Stay Program, please click here.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Florida Medical Association and the Florida Society of Pathologists. The Florida Medical Association is accredited by the ACCME to provide continuing medical education for physicians.
The Florida Medical Association designates this live activity for a maximum of 9.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CRITERIA FOR SUCCESS
Statements of credit/participation will be awarded based on the participant’s attendance at each session and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claim credit form at www.flpath.org/claimcme. If you have questions about this CME/CE activity, please contact the FSP at 904-309-6261. Credit must be claimed by July 28, 2021.
This activity is designed to meet the needs of practicing physicians, pathologists, and other specialists involved with pathology.
STATEMENT OF NEED
The field of pathology is constantly changing, and many of the most important advances in the field. In the setting of new technology, techniques and advancements in the field, practice gaps are inevitable. As such, pathologists require ongoing educational opportunities to stay current in order to maintain and improve their knowledge and competence in the field.
At the conclusion of this activity, all participants should be able to:
• Recognize histopathologic changes in tumor and normal epithelium after neoadjuvant systemic therapy.
• Review the reporting systems for breast specimens after neoadjuvant systemic therapy.
• Identify residual carcinoma after systemic therapy.
• Recognize diagnostic features of lesions of the breast.
• Review of breast cases with squamous metaplasia and metaplastic changes.
• Discuss changes in classifications of breast neoplasms from the 5th edition of WHO Classification of Breast Tumors
• Recognize differential diagnosis for spindle cell proliferations of the breast
• Identify the histopathologic and molecular correlates of vulvar squamous cell carcinoma precursor types.
• Identify and properly grade squamo-columnar junction specific cervical squamous intraepithelial lesions. (SIL)
• Recite the spectrum of non-HPV adenocarcinomas in the uterine cervix
• Recognize categories of undifferentiated or poorly differentiated carcinomas of the endometrium.
• Identify potential pitfalls in assessing glandular and squamous neoplasia of the vulva
• Distinguish variants of verruciform proliferations of the vulva
• Distinguish adenosarcoma from atypical endometrial polyp
• Recognize criteria for aggressive variants of low grade ovarian serous neoplasia
• Recognize unusual variants of epithelioid trophoblastic tumors
• Recognize variants of endometrioid and undifferentiated carcinomas of the uterus
• Recognize various pathologic and clinical features of Renal Cell Carcinoma subtypes
• Identify morphology and immunohistochemical analysis tests to appropriately classify Renal Cell Carcinoma (RCC)
• Describe the basics of medical malpractice law and the specific legal criteria that determine medical liability
• Recognize the typical timeline of a medical malpractice lawsuit
• Identify ways to minimize the emotional and psychological impact of a medical malpractice lawsuit on the pathologist and the pathologist's family
• Identify the origin and nature of “clear cell” neoplasia in the uterus and peritoneal cavity
• Recognize differences in acute versus prolonged treatment pathological findings in tissues
COMMERCIAL SUPPORT AND EDUCATIONAL GRANTS
This activity is supported by an educational grant from AstraZeneca. This activity is supported by in-kind product from Olympus.
The planners of this activity disclosed no financial relationships relevant to the content to be presented with the exception of Marilyn Bui, MD who disclosed the following Grant/Research Support: NCI/NIH Core Support Grant. Consultant: Epizyme, BMS, Hologic, ContexVision. Speaker's Bureau: Physicians Education Resource. Other Financial Support: Travel support to speak on behalf of Digital Pathology Associates
The faculty of this activity disclosed no financial relationships relevant to the content to be presented.
DISCLOSURE OF THE FLORIDA MEDICAL ASSOCIATION
It is the policy of the Florida Medical Association (FMA) to ensure independence, objectivity and scientific rigor in all approved CME content. CME faculty must present evidence-based data, clarify off-label product use and disclose all relevant financial relationships to the audience. The ideas and opinions expressed during jointly provided events do not necessarily reflect those of the FMA, and the FMA’s approval of course content for AMA PRA Category 1 Credits™. does not constitute an endorsement of the ideas, positions or statements contained therein. Every effort has been made to ensure that all information provided by the joint provider is accurate and current. However, FMA does not accept responsibility for errors or omissions and accepts no liability for any resulting loss or damage. Attendees agree to participate in this CME activity with full knowledge and awareness that they waive any claim they may have against the FMA for injury or other damage that may result in any way from their participation in this activity.
Make plans to join us for the Florida Society of Pathologists’ Summer Pathology Conference on July 17-18, 2021 at Eau Palm Beach Resort and Spa in Palm Beach, Florida. Connect with over 150 pathologists as you showcase your products and services.
We have added new and exciting sponsorship opportunities to allow you maximum exposure throughout the weekend. We look forward to working with you to secure your booth and confirm your participation in the conference.
For more information on exhibiting or sponsoring, please call 904-309-6220 or email firstname.lastname@example.org.
Agendia is a leading precision oncology company that develops genomic tests to help support physicians faced with complex treatment decisions. MammaPrint, the 70-gene signature is an FDA-cleared breast cancer recurrence assay, backed by peer-reviewed, prospective outcome data and is included in many national and international guidelines. BluePrint, the 80-gene molecular subtyping assay looks beyond the cell surface to identify Luminal-type, Basal-type and HER2-type breast cancer. Learn more at: www.agendia.com
Aiforia equips pathologists and scientists in preclinical, academic, and clinical labs with the most powerful deep learning artificial intelligence and cloud-based technology to increase the speed, accuracy and consistency of analyzing large and complex medical images across a variety of fields from oncology to neuroscience. Aiforia is composed of an ideal mix of scientists experienced in a variety of medical areas from pathology to cancer diagnostics, software developers who collectively hold over 100 years’ experience in artificial intelligence, and a business team with backgrounds in the pharmaceutical and biotechnology industries.
APS Medical Billing is a premier billing firm that provides expert billing and practice management solutions to pathology and laboratory practices nationwide. APS' clients range in size from a single-physician practice to large, multi-site academic departments, reference and independent labs. The scope of our billing services and proven strategies allow APS to effectively bill for professional, technical and global components of anatomic and clinical pathology services. Please visit our website at www.apsmedbill.com.
Our ambition is to push the boundaries of science to change the practice of medicine and transform the lives of cancer patients. We target the underlying biology of cancer in Immuno-Oncology, Tumor Drivers/Resistance, DNA Damage Response and Antibody Drug Conjugates. Utilizing precision medicine and biomarker-driven indications we look to dramatically improve five-year survival. Our focus on early disease stages and relapsed patients is to 1) identify and treat patients earlier with curative intent; and 2) support relapsed and refractory patients by tackling primary or acquired resistance.
Caris Life Sciences® is a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).
CSI Laboratories is a leading cancer testing and diagnostics laboratory trusted by pathologists, oncologists, and community hospitals throughout the U.S. and the Caribbean. For more than 24 years, our laboratories have employed advanced testing methods and a collaborative approach to deliver insightful results and rapid turnaround times. CSI provides a full complement of cancer testing under one roof, including flow cytometry, cytogenetic analysis, fluorescence in-situ hybridization (FISH), immunohistochemistry, molecular genetics, and consultations in the areas of hematopathology and surgical pathology. For more information, please visit www.csilaboratories.com.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 40 years. Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.
GenPath Oncology provides leading expertise in cancer diagnostics and offers a comprehensive portfolio to provide a single source solution laboratory for cancer patients' needs. GenPath is backed by a team of specialized pathologists and has experience in providing diagnostic oncology solutions, from routine clinical and special coagulation testing to complex genomic testing for tumor sequencing and hereditary cancer syndromes. GenPath offers oncologists and pathologists a variety of diagnostic solutions including morphological analysis, immunohistochemistry, FISH, flow cytometry, karyotyping, molecular analysis, and next generation sequencing. https://www.genpathdiagnostics.com/
Innovative Science Press is an organization dedicated to the advancement of physicians of all specialties by producing and disseminating educational text books. Innovative Science Press provides steep discounts to resident and fellow pathologists and donates frequently to the under-served countries. It is also dedicated to increasing women's awareness of maternal health and reproductive rights by targeted campaigns, funding and supporting their education, and by building partnerships with other health organizations.
Integrated Oncology’s commitment to scientific leadership provides clients with access to the latest developments in medical diagnostics, supported by industry-leading technical and professional expertise.
Our company has a distinctive, long-standing reputation for innovation and quality. Our specialized laboratories are the core of our company, providing high-quality testing services for our clients and their patients.
Molecular testing for indeterminate thyroid nodules are not all the same. ThyGeNEXT / ThyraMIR is the only testing platform that utilizes both mutational and microRNA markers to aid patient management. MicroRNA classification complements cytology and mutational analysis as well as risk-stratified patients with weak driver mutations, including RAS.
MedReceivables Advisor, LLC is a full service outsourcing medical billing company for the hospital based physician. Our company provides complete accounts receivable management services for hospital-based physicians.https://www.medreceivables.com/
For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, Merck continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.
NeoGenomics is a Florida-based premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic, and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-certified facilities in the US and offer global capabilities with laboratories in Switzerland and Singapore.
At ProAssurance, we work to protect medical professionals and support their patient safety efforts with custom healthcare professional liability insurance solutions. If a malpractice claim is made, we listen and provide experienced counsel, bringing clarity and fair treatment to the claims process. ProAssurance Group is rated A (Excellent) by AM Best.
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. We serve half of the physicians and hospitals in the United States.
What is included in the live meeting?
How will FSP keep attendees safe at the live meeting?
The Florida Society of Pathologists is committed to providing a healthy and safe environment for attendees of the live meeting. We are working diligently to comply with the recommendations and guidelines set by the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and the Florida and Palm Beach County Departments of Health to keep our attendees safe. The following protocols will be in place:
We will continue to monitor guidelines as they are updated to ensure our policies evolve with any changing guidelines. As the situation with the pandemic evolves, we will evaluate and adjust our policies with safety as its top priority. Updates will be provided as we get closer to the meeting dates. Attendees must adhere to all infectious disease protocols in place during the event, including those imposed by FSP, the venue, the county health department, and any state directives, and if they fail to do so, they will be ejected from the conference and the venue with no refund.
What will the Eau Palm Beach Resort be doing to keep guests safe?
The health and safety of the hoteliers, guests and community remains Eau Palm Beach Resort & Spa’s highest priority. By closely monitoring the latest guidelines by the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and the State of Florida and Palm Beach County Departments of Health, they have implemented the Safe Stay Program at Eau Palm Beach Resort & Spa. The Safe Stay Program includes:
This rigorous new protocol is intended to keep you safe and healthy during your visit so that you can focus on creating lasting memories at our Forbes Five-Star, AAA Five Diamond ocean retreat.
Can I bring a guest to FSP?
Guests are not permitted to attend the educational sessions or special events because of capacity restrictions due to COVID-19. Guests are welcome to come and stay at the Eau Palm Beach Resort with attendees.
What is the cancellation policy for the Conference?
A written notice of cancellation must be received by June 18, 2021 to receive a refund. Cancellations received prior to this date will be honored minus a $100 administration fee. Refunds will not be honored after June 18, 2021. Telephone cancellations cannot be accepted. Cancellation refunds will be processed within 30 days after the conclusion of the Conference.
Who do I contact for help?
FSP Member Login